Form 4: Director Willard H. Dere Acquires BioMarin Shares

BioMarin Pharmaceutical Inc. director Willard H. Dere was granted 7,490 restricted stock units as part of equity compensation.

Summary

• Director Willard H. Dere acquired 7,490 shares of BioMarin Pharmaceutical Inc. (BMRN) common stock.
• The transaction occurred on June 2, 2026, via a grant of restricted stock units.
• The acquisition price was $0, reflecting standard equity compensation for board members.
• Following this transaction, the director's total beneficial ownership stands at 46,440 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine director compensation.

Positives

• Increased alignment between director interests and shareholder value through equity ownership.
• Standardized compensation structure for board members.

Negatives

• None identified.

Risks

• General market risks associated with the biotechnology sector.
• Regulatory and clinical trial risks inherent to BioMarin's product pipeline.

Future Outlook

The filing does not provide forward-looking guidance regarding company performance, focusing solely on director equity holdings.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the biotechnology industry to ensure long-term alignment with corporate performance and shareholder interests.

Comparison to Industry Standards

• The grant of restricted stock units is consistent with standard compensation packages for independent directors at mid-to-large cap pharmaceutical companies.
• The transaction size is typical for annual director equity retainers in the sector.

Stakeholder Impact

• Minimal impact on stakeholders; reflects standard board compensation.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

BioMarin, BMRN, Insider Trading, Form 4, Director Compensation, Biotech